Incyte Remains Undervalued As Opzelura And Niktimvo Scale
Source: SeekingAlpha
2026-02-18 22:38:10 ET
Since my last article in August, "Incyte: Wall Street Underestimates Strength of Ruxolitinib Portfolio," Incyte shares ( INCY ) are up 19.1%....
Read the full article on Seeking Alpha
For further details see:
Incyte Remains Undervalued As Opzelura And Niktimvo Scale
VanEck Vectors Biotech ETF
NASDAQ: BBH
BBH Trading
1.67% G/L:
$193.755 Last:
1,923 Volume:
$193.16 Open:
